Here, we studied the expression of PHD2 and PHD3 in tumor samples from patients who had undergone radical or PN for localized ccRCC and analyzed their associations with RFS in two independent patient cohorts. The gene discussed is EGLN1; the disease is nonpapillary renal cell carcinoma.